Autopsy report · NCT06566092

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

“After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 2 years 3 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Iovance Biotherapeutics, Inc.

Sponsor type

Industry

Conditions

Soft Tissue Sarcoma; Primary Central Nervous System Carcinoma; Melanoma; Rhabdomyosarcoma; Ewing Sarcoma

Interventions

LN-145/LN-144

Participants

5

Sites

5

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.